Urabrelimab

厄比瑞利单抗

Report date: 2025/09/29 20:01:14

Base Information

Drug NameUrabrelimab
Drug Alias NameSRF-231
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionCluster of differentiation 47 inhibitorsImmunomodulators
TargetsCluster of differentiation 47
Therapy Area/IndicationsSolid tumoursHematologic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited States
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesSurface Oncology Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSurface Oncology Inc
Active IndicationsN/A
Inactive IndicationsSolid tumoursHematologic Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A